Targeting anticancer drug delivery to pancreatic cancer cells using a fucose-bound nanoparticle approach

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Yoshida, Makoto ^a,b   Takimoto, Rishu ^a,b   Murase, Kazuyuki ^a   Sato, Yasushi ^a   Hirakawa, Masahiro ^a,b   Tamura, Fumito ^a,b   Sato, Tsutomu ^a,b   Iyama, Satoshi ^a   Osuga, Takahiro ^a   Miyanishi, Koji ^a   Takada, Kohichi ^a   Hayashi, Tsuyoshi ^a   Kobune, Masayoshi ^b   Kato, Junji ^a,b  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CA 195 ANTIGEN; CISPLATIN; LIPOSOME; NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG TARGETING; DRUG UPTAKE; GROWTH INHIBITION; MOUSE; NONHUMAN; PANCREAS CANCER; PARTICLE SIZE; TREATMENT RESPONSE; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; CARBOCYANINES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CISPLATIN; DRUG DELIVERY SYSTEMS; FEMALE; FUCOSE; FUCOSYLTRANSFERASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPOSOMES; MICE; MICE, NUDE; NANOPARTICLES; PANCREATIC NEOPLASMS; RECEPTORS, CELL SURFACE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863826300     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039545     Document Type: Article

References (49)

1. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15: 2403-2413.
2. Keleg S, Büchler P, Ludwig R, Büchler MW, Friess H, (2003) Invasion and metastasis in pancreatic cancer. Mol Cancer 2: 14.
3. Rocha Lima CM, Centeno B, (2002) Update on pancreatic cancer. Curr Opin Oncol 14: 424-430.
4. Shore S, Raraty MG, Ghaneh P, Neoptolemos JP, (2003) Review article: chemotherapy for pancreatic cancer. Aliment Pharmacol Ther 18: 1049-1069.
5. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, et al. (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966.
6. Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364: 1817-1825.
7. Tawada K, Yamaguchi T, Kobayashi A, Ishihara T, Sudo K, et al. (2009) Changes in tumor vascularity depicted by contrast-enhanced ultrasonography as a predictor of chemotherapeutic effect in patients with unresectable pancreatic cancer. Pancreas 38: 30-35.
8. Miyanishi K, Ishiwatari H, Hayashi T, Takahashi M, Kawano Y, et al. (2008) A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization. Jpn J Clin Oncol 38: 268-274.
9. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, et al. (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2: 751-760.
10. Torchilin VP, (2010) Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol pp. 3-53.
11. Allen TM, (1994) Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 15: 215-220.
12. Senior JH, (1987) Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 3: 123-193.
13. Symon Z, Peyser A, Tzemach D, Lyass O, Sucher E, et al. (1999) Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 86: 72-78.
14. Moein Moghimi S, Hamad I, Bünger R, Andresen TL, Jørgensen K, et al. (2006) Activation of the human complement system by cholesterol-rich and PEGylated liposomes-modulation of cholesterol-rich liposome-mediated complement activation by elevated serum LDL and HDL levels. J Liposome Res 16: 167-174.
15. Damascelli B, Cantù G, Mattavelli F, Tamplenizza P, Bidoli P, et al. (2001) Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007): Phase II study of patients with squamous cell carcinoma of the head and neck and anal canal: preliminary evidence of clinical activity. Cancer 92: 2592-2602.
16. Jain RK, Stylianopoulos T, (2010) Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7: 653-664.
17. Polakis P, (2005) Arming antibodies for cancer therapy. Curr Opin Pharmacol 5: 382-387.
18. Wu AM, Senter PD, (2005) Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 23: 1137-1146.
19. von Mehren M, Adams GP, Weiner LM, (2003) Monoclonal antibody therapy for cancer. Annu Rev Med 54: 343-369.
20. Weiner LM, Adams GP, (2000) New approaches to antibody therapy. Oncogene 19: 6144-6151.
21. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, et al. (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146: 25-33.
22. Hakomori S, Kannagi R, (1983) Glycosphingolipids as tumor-associated and differentiation markers. J Natl Cancer Inst 71: 231-251.
23. Sugano K, Ohkura H, Maruyama T, Watanabe M, Hirohashi S, et al. (1988) Sandwich radioimmunometric assay with murine monoclonal antibody, NCC-ST-439, for serological diagnosis of human cancers. Jpn J Cancer Res 79: 618-625.
24. Hakomori S, (1989) Aberrant glycosylation in tumors and tumor-associated carbohydrate antigens. Adv Cancer Res 52: 257-331.
25. Tajiri M, Ohyama C, Wada Y, (2008) Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach. Glycobiology 18: 2-8.
26. Magnani JL, Brockhaus M, Smith DF, Ginsburg V, (1982) Detection of glycolipid ligands by direct binding of carbohydrate-binding proteins to thin-layer chromatograms. Methods Enzymol 83: 235-241.
27. Koprowski H, Herlyn M, Steplewski Z, Sears HF, (1981) Specific antigen in serum of patients with colon carcinoma. Science 212: 53-55.
28. Nakao A, Oshima K, Nomoto S, Takeda S, Kaneko T, et al. (1998) Clinical usefulness of CA-19-9 in pancreatic carcinoma. Semin Surg Oncol 15: 15-22.
29. Becker DJ, Lowe JB, (2003) Fucose: biosynthesis and biological function in mammals. Glycobiology 13: 41R-53R.
30. Tonetti M, Sturla L, Bisso A, Zanardi D, Benatti U, et al. (1998) The metabolism of 6-deoxyhexoses in bacterial and animal cells. Biochimie 80: 923-931.
31. Wiese TJ, Dunlap JA, Yorek MA, (1994) L-fucose is accumulated via a specific transport system in eukaryotic cells. J Biol Chem 269: 22705-22711.
32. Deyasi SK, Aikat BK, Sengupta U, (1975) Serum fucose in the diagnosis of malignancy, and its relative merits. Indian J Pathol Bacteriol 18: 16-20.
33. Sakai T, Yamamoto K, Yokota H, Hakozaki-Usui K, Hino F, et al. (1990) Rapid, simple enzymatic assay of free L-fucose in serum and urine, and its use as a marker for cancer, cirrhosis, and gastric ulcers. Clin Chem 36: 474-476.
34. Sawke NG, Sawke GK, (2010) Serum fucose level in malignant diseases. Indian J Cancer 47: 452-457.
35. Mas E, Pasqualini E, Caillol N, El Battari A, Crotte C, et al. (1998) Fucosyltransferase activities in human pancreatic tissue: comparative study between cancer tissues and established tumoral cell lines. Glycobiology 8: 605-613.
36. Tsuchida A, Okajima T, Furukawa K, Ando T, Ishida H, et al. (2003) Synthesis of disialyl Lewis a (Le(a)) structure in colon cancer cell lines by a sialyltransferase, ST6GalNAc VI, responsible for the synthesis of alpha-series gangliosides. J Biol Chem 278: 22787-22794.
37. Miyazaki K, Ohmori K, Izawa M, Koike T, Kumamoto K, et al. (2004) Loss of disialyl Lewis(a), the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulin-like lectin-7 (Siglec-7) associated with increased sialyl Lewis(a) expression on human colon cancers. Cancer Res 64: 4498-4505.
38. Aubert M, Panicot-Dubois L, Crotte C, Sbarra V, Lombardo D, et al. (2000) Peritoneal colonization by human pancreatic cancer cells is inhibited by antisense FUT3 sequence. Int J Cancer 88: 558-565.
39. Hirai M, Minematsu H, Kondo N, Oie K, Igarashi K, et al. (2007) Accumulation of liposome with Sialyl Lewis X to inflammation and tumor region: application to in vivo bio-imaging. Biochem Biophys Res Commun 353: 553-558.
40. Lee SJ, Evers S, Roeder D, Parlow AF, Risteli J, et al. (2002) Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science 295: 1898-1901.
41. Haltiwanger RS, Lehrman MA, Eckhardt AE, Hill RL, (1986) The distribution and localization of the fucose-binding lectin in rat tissues and the identification of a high affinity form of the mannose/N-acetylglucosamine-binding lectin in rat liver. J Biol Chem 261: 7433-7439.
42. Haltiwanger RS, Hill RL, (1986) The isolation of a rat alveolar macrophage lectin. J Biol Chem 261: 7440-7444.
43. Lehrman MA, Haltiwanger RS, Hill RL, (1986) The binding of fucose-containing glycoproteins by hepatic lectins. The binding specificity of the rat liver fucose lectin. J Biol Chem 261: 7426-7432.
44. Haltiwanger RS, Hill RL, (1986) The ligand binding specificity and tissue localization of a rat alveolar macrophage lectin. J Biol Chem 261: 15696-15702.
45. Kawakami S, Wong J, Sato A, Hattori Y, Yamashita F, et al. (2000) Biodistribution characteristics of mannosylated, fucosylated, and galactosylated liposomes in mice. Biochim Biophys Acta 1524: 258-265.
46. Gunn FJ, Tate CG, Henderson PJ, (1994) Identification of a novel sugar-H+ symport protein, FucP, for transport of L-fucose into Escherichia coli. Mol Microbiol 12: 799-809.
47. Dang S, Sun L, Huang Y, Lu F, Liu Y, et al. (2010) Structure of a fucose transporter in an outward-open conformation. Nature 467: 734-738.
48. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, et al. (2010) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 56: e1-48.
49. Sagawa T, Yamada Y, Takahashi M, Sato Y, Kobune M, et al. (2008) Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice. Hepatology 48: 828-840.